# Edgewise Therapeutics, Inc.: overview

EWTX · Nasdaq · CIK 1710072 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ewtx.md) · [Financials](/companies/ewtx/financials.md) · [Filings](/companies/ewtx/filings.md) · [Insiders](/companies/ewtx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.36)](/filings/0001104659-25-107427.md) | not reported | [(0.43)](/filings/0001104659-26-056713.md) | [(0.34)](/filings/0001104659-26-091670.md) | [(0.39)](/filings/0001104659-25-107427.md) | not reported | [(0.46)](/filings/0001104659-26-056713.md) | [(0.53)](/filings/0001104659-26-091670.md) |
| Free cash flow | $m | [(27.9) d](/filings/0001104659-25-107427.md) | [(27.2) d](/filings/0001104659-26-020112.md) | [(37.9)](/filings/0001104659-26-056713.md) | [(32.6) d](/filings/0001104659-26-091670.md) | [(34.9) d](/filings/0001104659-25-107427.md) | [(38.7) d](/filings/0001104659-26-020112.md) | [(42.8)](/filings/0001104659-26-056713.md) | [(42.5) d](/filings/0001104659-26-091670.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.14)](/filings/0001558370-23-001895.md) | [(1.26)](/filings/0001558370-24-001467.md) | [(1.57)](/filings/0001104659-26-020112.md) | [(1.45)](/filings/0001104659-26-020112.md) | [(1.63)](/filings/0001104659-26-020112.md) |
| Free cash flow | $m | [(34.2)](/filings/0001558370-23-001895.md) | [(58.2)](/filings/0001558370-24-001467.md) | [(97.7)](/filings/0001104659-26-020112.md) | [(110)](/filings/0001104659-26-020112.md) | [(144)](/filings/0001104659-26-020112.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ewtx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $630.5m | 15,518,492 |  | Unchanged |
| [Paradigm Biocapital Advisors LP](/funds/1855655.md) | 2026-06-30 | $415.1m | 10,215,455 |  | Added +2,850,417 |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $341.0m | 8,392,730 |  | Reduced −2,035,707 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $268.4m | 6,606,336 |  | Added +133,345 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $246.9m | 6,075,331 |  | Not compared |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $223.0m | 5,489,135 |  | Added +4,472,083 |
| [NOVO HOLDINGS A/S](/funds/1388325.md) | 2026-06-30 | $217.4m | 5,350,000 |  | Unchanged |
| [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $192.1m | 4,728,623 |  | Added +250,681 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $186.3m | 5,915,556 |  | Not compared |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $177.7m | 4,373,974 |  | Reduced −50,000 |

## Recent filings

[All 416 filings](/companies/ewtx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 12:05 ET | [10-Q](/filings/0001104659-26-091670.md) | Quarterly report, period 2026-06-30 | 0001104659-26-091670 |
| 2026-08-06 | 12:05 ET | [8-K](/filings/0001104659-26-091671.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091671 |
| 2026-07-16 | 12:01 ET | [8-K/A](/filings/0001104659-26-084088.md) | 9.01 Financial statements and exhibits | 0001104659-26-084088 |
| 2026-07-13 | 12:37 ET | [8-K](/filings/0001104659-26-082902.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-082902 |
| 2026-06-05 | 20:33 ET | [8-K](/filings/0001104659-26-071011.md) | 5.07 Shareholder vote results | 0001104659-26-071011 |
| 2026-06-01 | 12:51 ET | [8-K](/filings/0001193125-26-249951.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-249951 |
| 2026-05-07 | 13:20 ET | [8-K](/filings/0001104659-26-056783.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-056783 |
| 2026-05-07 | 12:09 ET | [10-Q](/filings/0001104659-26-056713.md) | Quarterly report, period 2026-03-31 | 0001104659-26-056713 |
| 2026-04-27 | 20:49 ET | [SCHEDULE 13D/A](/filings/0001388325-26-000014.md) | Ownership report, active investor, amended | 0001388325-26-000014 |
| 2026-04-23 | 20:06 ET | [DEF 14A](/filings/0001104659-26-047688.md) | Proxy statement, period 2026-06-04 | 0001104659-26-047688 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-020112.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1710072
- Tickers: EWTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.